Not surprisingly, in a second breast cancer cell line, HCC1937 (estrogen receptor (ER) and HER-2 negative), we observed very little sensitivity to lapatinib; and no sensitivity in the LCL derived from the same patient (Figure 3A). This evidence concerns the gene ERBB2 and breast cancer.